Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences Inc (NQ: ENSC )

0.9110 -0.2290 (-20.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 382,702
Open 1.140
Bid (Size) 0.9002 (2)
Ask (Size) 0.9099 (10)
Prev. Close 1.140
Today's Range 0.8500 - 1.170
52wk Range 0.7650 - 37.32
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing
Via ACCESSWIRE

Performance

YTD
-90.51%
-90.51%
1 Month
+3.10%
+3.10%
3 Month
-49.39%
-49.39%
6 Month
-61.40%
-61.40%
1 Year
-96.93%
-96.93%

More News

Read More
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States
Via ACCESSWIRE
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study
Via ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
Via ACCESSWIRE
Why Netflix Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360
Via ACCESSWIRE
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium
Via ACCESSWIRE
Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study
Via ACCESSWIRE
Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023
Via ACCESSWIRE
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies
Via ACCESSWIRE
Ensysce Presents "A New Generation of Safer Pain Treatments"
Via ACCESSWIRE
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium
Via ACCESSWIRE
Ensysce Biosciences Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Ensysce Biosciences Announces IRB Approval of Key Study Protocol
Via ACCESSWIRE
Ensysce Biosciences Announces Engagement of Alacrita Consulting
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.